This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Paintlia, A. S. Articles by Singh, A. K. Search for Related Content PubMed PubMed Citation Articles by Paintlia, A. S. Articles by Singh, A. K.

(American Journal of Pathology. 2006;169:1012-1025.)
© 2006 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2006.051309

Immunomodulatory Effect of Combination Therapy with Lovastatin and 5-Aminoimidazole-4-Carboxamide-1-ß-D-Ribofuranoside Alleviates Neurodegeneration in Experimental Autoimmune Encephalomyelitis

Ajaib S. Paintlia^*, Manjeet K. Paintlia^*, Inderjit Singh^* and Avtar K. Singh

From the Departments of Pediatrics^* and Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston; and the Ralph H. Johnson Veteran’s Administration Medical Center, Charleston, South Carolina

Combination therapy with multiple sclerosis (MS) therapeutics is gaining momentum over monotherapy for improving MS. Lovastatin, an HMG-CoA reductase inhibitor (statin), was immunomodulatory in an experimental autoimmune encephalomyelitis (EAE) model of MS. Lovastatin biases the immune response from Th1 to a protective Th2 response in EAE by a different mechanism than 5-aminoimidazole-4-carboxamide-1-ß-D-ribofuranoside, an immunomodulating agent that activates AMP-activated protein kinase. Here we tested these agents in combination in an EAE model of MS. Suboptimal doses of these drugs in combination were additive in efficacy against the induction of EAE; clinical symptoms were delayed and severity and duration of disease was reduced. In the central nervous system, the cellular infiltration and proinflammatory immune response was decreased while the anti-inflammatory immune response was increased. Combination treatment biased the class of elicited myelin basic protein antibodies from IgG2a to IgG1 and IgG2b, suggesting a shift from Th1 to Th2 response. In addition, combination therapy lessened inflammation-associated neurodegeneration in the central nervous system of EAE animals. These effects were absent in EAE animals treated with either drug alone at the same dose. Thus, our data suggest that agents with different mechanisms of action such as lovastatin and 5-aminoimidazole-4-carboxamide-1-ß-D-ribofuranoside, when used in combination, could improve therapy for central nervous system demyelinating diseases and provide a rationale for testing them in MS patients.

This article has been cited by other articles:

				A. S. Paintlia, M. K. Paintlia, A. K. Singh, and I. Singh Inhibition of Rho Family Functions by Lovastatin Promotes Myelin Repair in Ameliorating Experimental Autoimmune Encephalomyelitis Mol. Pharmacol., May 1, 2008; 73(5): 1381 - 1393. [Abstract] [Full Text] [PDF]